You searched for "regulation"
Incomplete teprotumumab treatment for thyroid eye disease
This is a multi-centre retrospective analysis of clinical outcomes in patients who were on teprotumumab for thyroid eye disease but had the usual regime of eight infusions, three weeks apart, interrupted due to COVID-19. Manufacturing was suspended between Dec 2020...OSA regulatory advice baton moves to new expert
The OSA’s regulatory advice service – a key element of membership for many optical businesses – is moving to safe new hands as Ann Blackmore retires after six years at the helm. Ann’s extensive knowledge of the optical landscape, both...An update on idiopathic intracranial hypertension
The incidence of Idiopathic intracranial hypertension (IIH) is increasing, likely in line with the worldwide epidemic of obesity. To date, there have been revisions in the terminology used and diagnostic criteria for IIH; these recognise the need to exclude secondary...Regulatory drug evaluations and expedited review initiatives: EU and US perspectives
The European Medicines Agency (EMA) and United States Food and Drug Administration (FDA) each conduct independent assessments of benefit-risk profile when evaluating applications to market new or modified medicines, and their respective decision-making is guided by distinct legislation, procedures and...Tough gig
‘The times they are a-changin’. The words of this Dylan classic resonate down the decades, and in the light of recent events, speak eloquently to life in 2022. It feels like a lifetime of change has passed since the Eye...
Resolution of mid-peripheral schisis in x-linked retinoschisis with the use of dorzolamide
X-linked retinoschisis (XLRS) is an early onset hereditary retinal dystrophy. It is caused by mutations of the RS1 gene. Common manifestations of XLRS are schitic lesions at the macula, as well as infero-temporal schisis. Carbonic anhydrase inhibitors have previously been...
